keyword
MENU ▼
Read by QxMD icon Read
search

High dose influenza vaccine

keyword
https://www.readbyqxmd.com/read/29452380/relative-vaccine-effectiveness-of-high-dose-versus-standard-dose-influenza-vaccines-among-veterans-health-administration-patients
#1
Yinong Young-Xu, Robertus Van Aalst, Salaheddin M Mahmud, Kenneth J Rothman, Julia Thornton Snider, Daniel Westreich, Vincent Mor, Stefan Gravenstein, Jason K H Lee, Edward W Thommes, Michael D Decker, Ayman Chit
Background: To examine whether a high-dose inactivated influenza vaccine was more efficacious in preventing hospitalizations than a standard-dose vaccine in the Veterans Health Administration (VHA) senior population. Methods: This study estimated the relative vaccine effectiveness (rVE) of high-dose versus standard-dose using a retrospective cohort of VHA patients 65 years of age or older in the 2015-16 influenza season. To adjust for measured confounders, we matched each high-dose recipient with up to four standard-dose recipients vaccinated at the same location within a two-week period and having two or more pre-existing medical co-morbidities...
February 14, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29451833/development-and-pilot-testing-of-a-text-message-vaccine-reminder-system-for-use-during-an-influenza-pandemic
#2
Jonathan D Lehnert, Alex Shevach, Sydney Walker, Rose Wang, Thomas J Fitzgerald, Samuel B Graitcer
In an influenza pandemic, two vaccine doses administered 21 days apart may be needed for individuals of all ages to achieve seroprotection. Achieving dose-series completion can be challenging even for routinely recommended vaccines. To prepare for a two-dose influenza pandemic vaccine campaign and promote dose-series completion and correct dosing intervals, CDC and its partners developed a text message-based vaccine reminder system to remind persons who receive a first dose of pandemic influenza vaccine to receive the second dose...
February 16, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29445377/mouse-models-of-influenza-infection-with-circulating-strains-to-test-seasonal-vaccine-efficacy
#3
Helen T Groves, Jacqueline U McDonald, Pinky Langat, Ekaterina Kinnear, Paul Kellam, John McCauley, Joanna Ellis, Catherine Thompson, Ruth Elderfield, Lauren Parker, Wendy Barclay, John S Tregoning
Influenza virus infection is a significant cause of morbidity and mortality worldwide. The surface antigens of influenza virus change over time blunting both naturally acquired and vaccine induced adaptive immune protection. Viral antigenic drift is a major contributing factor to both the spread and disease burden of influenza. The aim of this study was to develop better infection models using clinically relevant, influenza strains to test vaccine induced protection. CB6F1 mice were infected with a range of influenza viruses and disease, inflammation, cell influx, and viral load were characterized after infection...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29444167/rotavirus-vaccine-coverage-and-factors-associated-with-uptake-using-linked-data-ontario-canada
#4
Sarah E Wilson, Hannah Chung, Kevin L Schwartz, Astrid Guttmann, Shelley L Deeks, Jeffrey C Kwong, Natasha S Crowcroft, Laura Wing, Karen Tu
BACKGROUND: In August 2011, Ontario, Canada introduced a rotavirus immunization program using Rotarix™ vaccine. No assessments of rotavirus vaccine coverage have been previously conducted in Ontario. METHODS: We assessed vaccine coverage (series initiation and completion) and factors associated with uptake using the Electronic Medical Record Administrative data Linked Database (EMRALD), a collection of family physician electronic medical records (EMR) linked to health administrative data...
2018: PloS One
https://www.readbyqxmd.com/read/29438483/statin-use-and-risks-of-influenza-related-outcomes-among-older-adults-receiving-standard-dose-or-high-dose-influenza-vaccines-through-medicare-during-2010-2015
#5
Hector S Izurieta, Yoganand Chillarige, Jeffrey A Kelman, Richard Forshee, Yandong Qiang, Michael Wernecke, Jill M Ferdinands, Yun Lu, Yuqin Wei, Wenjie Xu, Michael Lu, Alicia Fry, Douglas Pratt, David K Shay
Background: Statins are used to reduce cardiovascular disease risk. Recent studies suggest that statin use may be associated with an increased influenza risk among influenza vaccinees. We used Medicare data to evaluate associations between statins and risks of influenza-related encounters among vaccinees. Methods: In this retrospective cohort study, we identified Medicare beneficiaries aged >65 years who received high-dose (HD) or standard-dose (SD) influenza vaccines at pharmacies from 2010-11 through 2014-15...
February 9, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29425074/iga-polymerization-contributes-to-efficient-virus-neutralization-on-human-upper-respiratory-mucosa-after-intranasal-inactivated-influenza-vaccine-administration
#6
Yoshihiko Terauchi, Kaori Sano, Akira Ainai, Shinji Saito, Yuki Taga, Kiyoko Ogawa-Goto, Shin-Ichi Tamura, Takato Odagiri, Masato Tashiro, Mikiya Fujieda, Tadaki Suzuki, Hideki Hasegawa
Unlike the current injectable influenza vaccines, intranasally administered influenza vaccines induce influenza virus-specific IgA antibodies in the local respiratory mucosa as well as IgG antibodies in the systemic circulation. Our previous study showed that after five volunteers underwent intranasal administration with inactivated H3N2 or H5N1 vaccines, their IgA antibodies on the upper respiratory tract were present as monomers, dimers, and multimers (trimers and tetramers). Moreover, the multimers associated with the highest virus neutralizing activity...
February 9, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29388196/vaccines-for-preventing-influenza-in-healthy-adults
#7
REVIEW
Vittorio Demicheli, Tom Jefferson, Eliana Ferroni, Alessandro Rivetti, Carlo Di Pietrantonj
BACKGROUND: The consequences of influenza in adults are mainly time off work. Vaccination of pregnant women is recommended internationally. This is an update of a review published in 2014. Future updates of this review will be made only when new trials or vaccines become available. Observational data included in previous versions of the review have been retained for historical reasons but have not been updated due to their lack of influence on the review conclusions. OBJECTIVES: To assess the effects (efficacy, effectiveness, and harm) of vaccines against influenza in healthy adults, including pregnant women...
February 1, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29369776/successful-treatment-of-marburg-virus-with-orally-administrated-t-705-favipiravir-in-a-mouse-model
#8
Wenjun Zhu, Zirui Zhang, Shihua He, Gary Wong, Logan Banadyga, Xiangguo Qiu
Filoviruses, such as Marburg and Ebola viruses, cause severe disease in humans with high case fatality rates and are therefore considered biological threat agents. To date, no licensed vaccine or therapeutic exists for their treatment. T-705 (favipiravir) is a pyrazinecarboxamide derivative that has shown broad antiviral activity against a number of viruses and is clinically licenced in Japan to treat influenza. Here we report the efficacy of T-705 against Marburg virus infection in vitro and in vivo. Notably, oral administration of T-705 beginning one or two days post-infection and continuing for eight days resulted in complete survival of mice that had been intraperitoneally infected with mouse-adapted Marburg virus (variant Angola)...
January 21, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29336924/immunization-of-preterm-infants-with-gsk-s-hexavalent-combined-diphtheria-tetanus-acellular-pertussis-hepatitis-b-inactivated-poliovirus-haemophilus-influenzae-type-b-conjugate-vaccine-a-review-of-safety-and-immunogenicity
#9
Felix Omeñaca, Liliana Vázquez, Pilar Garcia-Corbeira, Narcisa Mesaros, Linda Hanssens, Jan Dolhain, Ivonne Puente Gómez, Johannes Liese, Markus Knuf
BACKGROUND: Infants with history of prematurity (<37 weeks gestation) and low birth weight (LBW, <2500 g) are at high risk of infection due to functional immaturity of normal physical and immunological defense mechanisms. Despite current recommendations that infants with history of prematurity/LBW should receive routine immunization according to the same schedule and chronological age as full-term infants, immunization is often delayed. METHODS: Here we summarize 10 clinical studies and 15 years of post-marketing safety surveillance of GSK's hexavalent vaccine (DTPa-HBV-IPV/Hib), a combined diphtheria-tetanus-acellular-pertussis-hepatitis-B-inactivated-poliovirus-Haemophilus influenzae-type-b (Hib) conjugate vaccine, when administered alone, or co-administered with pneumococcal conjugate, rotavirus, and meningococcal vaccines and respiratory syncytial virus IgG to infants with history of prematurity/LBW in clinical trials...
January 11, 2018: Vaccine
https://www.readbyqxmd.com/read/29299891/the-korean-influenza-national-immunization-program-history-and-present-status
#10
REVIEW
Jae Won Yun, Ji Yun Noh, Joon Young Song, Chaemin Chun, Yunju Kim, Hee Jin Cheong
The Korean influenza national immunization program was first established as an interim program in 1997, administering the influenza vaccine to low-income elderly adults. In 2005, the program assumed its present form of providing free influenza vaccination to adults aged ≥65 years. After turning over the influenza vaccination for elderly adults to the private sectors in 2015, the influenza vaccination coverage rate among this population increased to >80%. In addition, after the 2009 H1N1 influenza epidemic crisis, the vaccine was domestically produced...
December 2017: Infection & Chemotherapy
https://www.readbyqxmd.com/read/29287683/how-close-are-countries-of-the-who-european-region-to-achieving-the-goal-of-vaccinating-75-of-key-risk-groups-against-influenza-results-from-national-surveys-on-seasonal-influenza-vaccination-programmes-2008-2009-to-2014-2015
#11
Pernille Jorgensen, Jolita Mereckiene, Suzanne Cotter, Kari Johansen, Svetla Tsolova, Caroline Brown
BACKGROUND: Influenza vaccination is recommended especially for persons at risk of complications. In 2003, the World Health Assembly urged Member States (MS) to increase vaccination coverage to 75% among older persons by 2010. OBJECTIVE: To assess progress towards the 2010 vaccination goal and describe seasonal influenza vaccination recommendations in the World Health Organization (WHO) European Region. METHODS: Data on seasonal influenza vaccine recommendations, dose distribution, and target group coverage were obtained from two sources: European Union and European Economic Area MS data were extracted from influenza vaccination surveys covering seven seasons (2008/2009-2014/2015) published by the Vaccine European New Integrated Collaboration Effort and European Centre for Disease Prevention and Control...
December 26, 2017: Vaccine
https://www.readbyqxmd.com/read/29285399/fighting-against-a-protean-enemy-immunosenescence-vaccines-and-healthy-aging
#12
Giuseppe Del Giudice, Jörg J Goronzy, Beatrix Grubeck-Loebenstein, Paul-Henri Lambert, Tomas Mrkvan, Jeffrey J Stoddard, T Mark Doherty
The progressive increase of the aged population worldwide mandates new strategies to ensure sustained health and well-being with age. The development of better and/or new vaccines against pathogens that affect older adults is one pivotal intervention in approaching this goal. However, the functional decline of various physiological systems, including the immune system, requires novel approaches to counteract immunosenescence. Although important progress has been made in understanding the mechanisms underlying the age-related decline of the immune response to infections and vaccinations, knowledge gaps remain, both in the areas of basic and translational research...
2018: NPJ Aging and Mechanisms of Disease
https://www.readbyqxmd.com/read/29259264/skin-immunization-by-microneedle-patch-overcomes-statin-induced-suppression-of-immune-responses-to-influenza-vaccine
#13
Elena V Vassilieva, Shelly Wang, Song Li, Mark R Prausnitz, Richard W Compans
Recent studies indicated that in elderly individuals, statin therapy is associated with a reduced response to influenza vaccination. The present study was designed to determine effects on the immune response to influenza vaccination induced by statin administration in a mouse model, and investigate potential approaches to improve the outcome of vaccination on the background of statin therapy. We fed middle aged BALB/c mice a high fat "western" diet (WD) alone or supplemented with atorvastatin (AT) for 14 weeks, and control mice were fed with the regular rodent diet...
December 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29239682/safety-and-immunogenicity-of-a-seasonal-trivalent-inactivated-split-influenza-vaccine-a-phase-i-randomized-clinical-trial-in-healthy-serbian-adults
#14
Goran Stevanovic, Lidija Lavadinovic, Svetlana Filipovic Vignjevic, Renée Holt, Katarina Ilic, Francesco Berlanda Scorza, Erin Sparrow, Vera Stoiljkovic, Guido Torelli, Tamra Madenwald, Muriel Socquet, Aleksandra Barac, Yordanka Ilieva-Borisova, Mijomir Pelemis, Jorge Flores
This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy adults. The vaccine was manufactured in eggs by the Torlak Institute of Virology, Vaccines and Sera, Belgrade, Serbia and contained A/H1N1, A/H3N2 and B viruses. The clinical trial took place at the Clinical Center of Serbia in Belgrade. Sixty healthy volunteers, aged 18-45 years, were enrolled in the trial...
December 14, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29237061/the-comparative-effectiveness-of-high-dose-versus-standard-dose-influenza-vaccines-in-preventing-post-influenza-deaths
#15
Karl Madaras-Kelly, Richard Remington, Hayli Hruza, Dong Xu
No abstract text is available yet for this article.
December 9, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29230222/single-dose-of-consensus-hemagglutinin-based-virus-like-particles-vaccine-protects-chickens-against-divergent-h5-subtype-influenza-viruses
#16
Peipei Wu, Jihu Lu, Xuehua Zhang, Mei Mei, Lei Feng, Daxin Peng, Jibo Hou, Sang-Moo Kang, Xiufan Liu, Yinghua Tang
The H5 subtype highly pathogenic avian influenza (HPAI) virus is one of the greatest threats to global poultry industry. To develop broadly protective H5 subunit vaccine, a recombinant consensus HA sequence (rHA) was constructed and expressed in virus-like particles (rHA VLPs) in the baculovirus-insect cell system. The efficacy of the rHA VLPs vaccine with or without immunopotentiator (CVCVA5) was assessed in chickens. Compared to the commercial Re6 or Re6-CVCVA5 vaccines, single dose immunization of chickens with rHA VLPs or rHA-CVCVA5 vaccines induced higher levels of serum hemagglutinin inhibition titers and neutralization titers, mucosal antibodies, IFN-γ and IL-4 cytokines in sera, and cytotoxic T lymphocyte responses...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29223454/preparation-characterization-and-immunological-evaluation-of-alginate-nanoparticles-loaded-with-whole-inactivated-influenza-virus-dry-powder-formulation-for-nasal-immunization-in-rabbits
#17
Solmaz Dehghan, Masoumeh Tavassoti Kheiri, Khalil Abnous, Maryam Eskandari, Mohsen Tafaghodi
It has become important to explore more efficient and feasible influenza vaccines, since epidemics of influenza virus cause hundreds of thousands of deaths all around the world. Improving immunogenicity of parentral influenza vaccines has given rise to mucosal delivery routes. In this study, alginate nanoparticles (NPs) were efficiently synthetized by ionic gelation method and influenza virus and CpG ODN or Quillaja Saponin (QS) adjuvants were actively incorporated into alginate NPs. The prepared particles were evaluated for both humoral and cellular immune responses in rabbits' nostrils...
December 6, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/29214495/comparison-of-anti-influenza-virus-activity-and-pharmacokinetics-of-oseltamivir-free-base-and-oseltamivir-phosphate
#18
Jin Soo Shin, Keun Bon Ku, Yejin Jang, Yi-Seul Yoon, Daeho Shin, Oh Seung Kwon, Yun Young Go, Seong Soon Kim, Myoung Ae Bae, Meehyein Kim
Influenza viruses are major human respiratory pathogens that cause high morbidity and mortality worldwide. Currently, prophylactic vaccines and therapeutic antiviral agents are used to prevent and control influenza virus infection. Oseltamivir free base (OSV-FB), a modified generic antiviral drug of Tamiflu (oseltamivir phosphate, OSV-P), was launched in the Republic of Korea last year. Here, we examine the bioequivalence of these two compounds by assessing their antiviral efficacy in infected cells and in a mouse model...
December 2017: Journal of Microbiology / the Microbiological Society of Korea
https://www.readbyqxmd.com/read/29201630/avoidance-of-harm-from-treatment-for-anca-associated-vasculitis
#19
REVIEW
Catherine King, Lorraine Harper
Purpose of review With established immunosuppressant treatment regimens for anti-neutrophil cytoplasm antibody-associated vasculitides (AAV), prognosis has significantly improved. The mainstay of treatment still comprises high-dose corticosteroids and cyclophosphamide for severe forms, although rituximab is being increasingly utilised instead of cyclophosphamide as induction therapy. AAV patients experience an excess of infections, malignancies and cardiovascular events as compared to the general population, which is a combination of the systemic inflammatory process associated with vasculitis and the adverse events from treatment...
2017: Current Treatment Options in Rheumatology
https://www.readbyqxmd.com/read/29177407/a-two-centre-randomised-trial-of-an-additional-early-dose-of-measles-vaccine-effects-on-mortality-and-measles-antibody-levels
#20
Ane B Fisker, Eric Nebie, Anja Schoeps, Cesario Martins, Amabelia Rodrigues, Alphonse Zakane, Moubassira Kagone, Stine Byberg, Sanne M Thysen, Justin Tiendrebeogo, Boubacar Coulibaly, Osman Sankoh, Heiko Becher, Hilton C Whittle, Fiona R M van der Klis, Christine S Benn, Ali Sie, Olaf Müller, Peter Aaby
Background: Besides protecting against measles, measles vaccine (MV) may have beneficial non-specific effects. We tested the effect of an additional early MV on mortality and measles antibody levels. Methods: Children aged 4-7 months in two rural health and demographic surveillance sites in Burkina Faso and Guinea-Bissau were randomised 1:1 to an extra early standard dose of MV (Edmonston-Zagreb strain) or no extra MV 4 weeks after the third diphtheria-tetanus-pertussis-hepatitis B-Haemophilus-influenzae-type-b vaccine...
November 21, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
116341
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"